Nova Publishers
My Account Nova Publishers Shopping Cart
HomeBooksSeriesJournalsReference CollectionseBooksInformationSalesImprintsFor Authors
  Top » Catalog » Books » My Account  |  Cart Contents  |  Checkout   
Quick Find
Use keywords to find the product you are looking for.
Advanced Search
What's New? more
Fetal Alcohol Syndrome: Recognition, Differential Diagnosis and Long-Term Effects
Shopping Cart more
0 items
Shipping & Returns
Privacy Notice
Conditions of Use
Contact Us
Notifications more
NotificationsNotify me of updates to Burkitt Lymphoma: Updates in Etiology, Diagnosis, Molecular Genetics and Treatment Options
Tell A Friend
Tell someone you know about this product.
Burkitt Lymphoma: Updates in Etiology, Diagnosis, Molecular Genetics and Treatment Options
Retail Price: $160.00
10% Online Discount
You Pay:

Editors: Ling Zhang, M.D., and Lubomir Sokol, M.D., Ph.D. (Department of Hematopathology and Laboratory Medicine, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, FL, US, and others)
Book Description:
Burkitt lymphoma (BL) is a lymphoid neoplasm originating from a mature, follicular center B-cell that is phenotypically positive for CD10, BCL-6, LOM2, and HGAL, with a hallmark genetic translocation involving the MYC gene (at 8q24) and its partner – either immunoglobulin heavy chain (14q) or light chain (kappa at 2q and lambda at 22q) – and a very aggressive clinical nature. BL can be divided into three clinical subcategories: Endemic, sporadic and HIV/AIDS/immunodeficiency with prevalence in children, adolescents and young adults. Clinical manifestations could slightly be variable upon its clinical subcategories; however, they share certain similar features, e.g., fast growing mass, frequent extranodal presentation, are associated with EBV infection, and sensitive to tumor reduction therapy with a high risk of tumor lysis syndrome and uric acid nephropathy. It is important to differentiate BL from other aggressive types of B-cell lymphomas as with intensive, short-term chemotherapy, e.g., hyper-CVAD (hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, and cytarabine). Additionally, CNS prophylaxis BL showed a much better clinical response. Nearly all types of BL lack or dimly express BCL-2, differentiating it from other mimickers. A diagnostic challenging variant of BL – an MYC-negative harboring 11q abnormalities, namely “Burkitt-like lymphoma with an 11q aberration” – has been recently proposed. Novel next generation sequencing and gene expression profiling has brought about new insights into BL. TCF3(E2A), a transcription factor involving the regulation of lymphoid cell survival and proliferation, its negative regulator known as ID3, and the downstream gene CCND3 were also frequently mutated in cases of BL. The characterization of molecular biology and the genetic profile of BL leads to the future of personalized medicine and targeted therapy. This book focuses on the epidemiology, etiology, clinical presentations/staging, differential diagnoses, MYC-driven pathogenesis and therapeutic options concerning BL. These updates in BL and associated EBV- or MYC-positive diseases will benefit trainees, physicians and basic scientists who engage in the diagnosis, treatment, and novel drug development for this disease. (Nova Medicine and Health)

We’ve partnered with Copyright Clearance Center to make it easy for you to request permissions to reuse Nova content.
For more information, click here or click the "Get Permission" button below to link directly to this book on Copyright Clearance Center's website.

Table of Contents:

Chapter 1. Epidemiology and Etiology of Burkitt Lymphoma (pp. 1-26)
(Vania Phuoc and Lubomir Sokol)

Chapter 2. Clinical Presentation of Burkitt Lymphoma (pp. 27-44)
(Onyee Chan)

Chapter 3. Staging and Prognosis of Burkitt Lymphoma (pp. 45-64)
(Onyee Chan)

Chapter 4. Diagnostic Approaches to Burkitt Lymphoma and Its Mimickers (pp. 65-118)
(Melinda Fang, Kenian Liu, Robert Seifert and Ling Zhang)

Chapter 5. Updated Molecular Genetics of Burkitt Lymphoma (pp. 119-146)
(Melinda Fang, Kenian Liu and Ling Zhang)

Chapter 6. Molecular Pathogenesis of MYC in Burkitt and High-Grade Lymphoma (pp. 147-164)
(Seongseok Yun and Ling Zhang)

Chapter 7. Therapy in Burkitt Lymphoma (pp. 165-192)
(D. Alan Kerr II and Lubomir Sokol)

About the Editors (pp. 193-194)

Index (pp. 195)

Total Pages: 203

      Cancer Etiology, Diagnosis and Treatments
   Binding: Hardcover
   Pub. Date: 2018-September
   ISBN: 978-1-53614-164-1
   Status: AV
Status Code Description
AN Announcing
FM Formatting
PP Page Proofs
FP Final Production
EP Editorial Production
PR At Prepress
AP At Press
AV Available
Special Focus Titles
01.Violent Communication and Bullying in Early Childhood Education
02.Cultural Considerations in Intervention with Women and Children Exposed to Intimate Partner Violence
03.Chronic Disease and Disability: The Pediatric Lung
04.Fruit and Vegetable Consumption and Health: New Research
05.Fire and the Sword: Understanding the Impact and Challenge of Organized Islamism. Volume 2

Nova Science Publishers
© Copyright 2004 - 2021

Burkitt Lymphoma: Updates in Etiology, Diagnosis, Molecular Genetics and Treatment Options